Milestone Pharmaceuticals (MIST) said Friday it has launched a public offering of its common shares, as well as accompanying series A and B warrants to purchase such shares.
The company plans to use the net proceeds, along with existing cash and cash equivalents, to fund the clinical development and commercial launch of etripamil in its lead indication of paroxysmal supraventricular tachycardia, among other things.
Milestone Pharmaceuticals shares were down nearly 15% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.